HIP2101
Phase 3Small molecule
Hanmi Pharmaceutical Company LimitedHIP2101 is one of 10 small molecule programs targeting Chronic Gastritis. It is currently in Phase 3.
1
Indications
2
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Chronic Gastritis
#DrugCompanyPhaseTrials
1Nexium
DDexcel Pharma Technologies Ltd.
Approved
Mucosta
OtsukaPhase 3
DWP14012
Daewoong Pharmaceutical Co. LTD.Phase 3
Test
RRespirent Pharmaceuticals Co Ltd.
Phase 3
Reference
RRespirent Pharmaceuticals Co Ltd.
Phase 3
HIP2101
Hanmi Pharmaceutical Company LimitedPhase 3
DW1903
Daewon Pharmaceutical Co., Ltd.Phase 3
RLD2101
Hanmi Pharmaceutical Company LimitedPhase 3
DW1903-R1
Daewon Pharmaceutical Co., Ltd.Phase 3
Stillen
Chong Kun Dang PharmaceuticalPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HIP2101. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details